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particular to prevent the spread of resistant strains in the recent human H7N9 outbreak. We
tailored a pyrosequencing assay to reveal neuraminidase R292K, a resistant marker found in
one isolate from China, and demonstrated its performance in both sensitivity and specificity.
In addition, a semi-nested polymerase chain reaction was applied, which enhanced the detec-
tion rate by at least 10-fold. We validated this assay by examining the marker in Taiwan’s first
imported human case and found R and K in quasispecies.
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Germany).The emerging avian influenza A (H7N9) virus has been re-
ported to infect humans in China since February 2013.1
Taiwan is located in proximity to mainland China, and is
closely connected in business; therefore, Taiwan is highly
alerted to any reported cases of this disease. The Taiwan
Centers for Disease Control (CDC) and its collaborating
laboratories of virology began a real-time polymerase chain
reaction (PCR)-based influenza A H7N9 virus surveillance for
H7N9 probables from pneumonia cases with unspecified
pathogens. The laboratories examined clinical samples
including throat swabs, sputum, and tracheal aspirates. On
April 24, 2013, a sputum specimen collected from a patient
in Taipei City, Taiwan tested positive for H7N9.2,3
Several studies reported that E119V, I222V, R224K,
R292K, and N294S are markers for N2 in reducing oselta-
mivir susceptibility.4e6 N9 is known to be genetically con-
nect to N2.7 Although most H7N9 human isolates thus far do
not contain any of these markers, one isolate from
Shanghai, China showed 292K in its neuraminidase (NA)
gene. We further examined this marker by NA pyrose-
quencing of the first Taiwanese sputum specimen and also
located R292K in the quasispecies of the virus population.
Materials and methods
Clinical specimen and RNA extraction
The sputum specimen submitted to the Taiwan CDC, which
was the first laboratory-confirmed case of avian influenza A
(H7N9) virus infection in Taiwan, was used for this study.
The extraction of the viral RNA was conducted by the
Taiwan CDC with the MagNA Pure LC automated nucleicFigure 1. Sensitivity and specificity of reverse transcription poly
primers were designed for detecting an emerging H7N9 virus NA g
selected Taiwanese seasonal influenza A neuraminidase (NA) plasm
126/09) were amplified and analyzed in 1% agarose gel. Each lane
product is indicated by an asterisk. A full-length (FL) NA product wacid extraction system (Roche Diagnostics, Mannheim,
Primer design
Human, avian, and environment H7N9 NA sequences re-
ported in China8 and 21 NA sequences of Eurasian lineage of
avian influenza virus9 were retrieved from the Global
Initiative on Sharing Avian Influenza Database and aligned
by BioEdit v. 7.0.4.10 The consensus regions that covered N9
were chosen for primer design. The consensus-degenerated
primers were designed to target an NA fragment 488 nu-
cleotides long, encompassing the R292K mutation site
(Fig. 1A).
Reverse transcriptionepolymerase chain reaction
SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad,
CA, USA) was used to perform cDNA synthesis according to
the manufacturer protocol, with a 1 mL RNA template and a
HuN9NA-F460-biot primer (Table 1). The PCR was executed
using a proofreading KOD-Plus DNA polymerase (1 U) in a
50 mL reaction containing dNTPs (0.2 mM), MgSO4 (1 mM),
two primers (HuN9NA-F460-biot and HuN9NA-R947, 0.3 mM
each), and 2 mL of cDNA in a PCR buffer under the following
cycling conditions: 94C for 2 minutes, 35 cycles of 94C for
30 seconds, 55C for 30 seconds, 68C for 1 minute, and a
final elongation step of 68C for 7 minutes. The PCR con-
dition was the same for the semi-nested PCR with the
HuN9NA-F460-biot and HuN9NA-R919 primers (Table 1). The
PCR products were analyzed by gel electrophoresis on a 1%
agarose gel containing 2 mg/mL ethidium bromide. For
Sanger sequencing, the PCR products were purified using
the QIAquick gel extraction kit (Qiagen, Valencia, CA, USA).merase chain reaction (PCR). (A) The reverse transcription-PCR
ene. (B and C) A serially diluted N9 plasmid, PR8 plasmid, and
ids (including one H1N1pdm - A/Taiwan/126/2009 labeled as
was loaded with 5 mL of a PCR product, and the expected PCR
as obtained from each strain tested as a loading control.
Table 1 RT-PCR and pyrosequencing primers for avian influenza A (H7N9) virus targeting the neuraminidase (NA) gene
Primer Sequence (50 to 30) Nt positiona DNA size
Reverse transcription
HuN9NA-F460-biot CTGATAAGCTGGCCACTATCATCAC 460e484
PCR
HuN9NA-F460-biot CTGATAAGCTGGCCACTATCATCAC 460e484 488 bp
HuN9NA-R947 CTGCATATRTAYTGACTAGTRTGTGTCA 947e920
Semi-nested PCR
HuN9NA-F460-biot CTGATAAGCTGGCCACTATCATCAC 460e484 460 bp
HuH7NA-R919 TTGCTACTGGRTCTATCTGAAYCACT 919e894
Pyrosequencing
HuN9NA-292&294-R893-seq GGTCTATTTGAGCCCTGCCA 893e874
a Nt position is numbered by A/Taiwan/1/2013(H7N9) NA cds, reference no. EPI ISL140356 in GISAID.
Pyrosequencing for H7N9 oseltamivir-resistant 467The nucleotide sequence of the purified fragments was
determined using an automated ABI3730 DNA sequencer
(PE-Applied Biosystems, Foster City, CA, USA). The full-
length cDNA of the H7N9 NA gene was amplified with uni-
versal primers11 and cloned using the pGEM-T Easy Vector
Systems (Promega, Madison, WI, USA). A plasmid carrying
the R292K mutation was used to validate the sensitivity of
the PCR and pyrosequencing assay. The NA plasmids from
pandemic H1N1 (A/Taiwan/126/2009), and seasonal H1N1
(A/Taiwan/141/2002), and H3N2 (A/Taiwan/3446/2002)
viruses were used for evaluating the specificity of the PCR
primers.
Pyrosequencing assay
The pyrosequencing assay was performed according to the
manufacturer instructions by using the PyroMark Q24 sys-
tem (Qiagen). In brief, 10 mL of a biotinylated PCR product
was bound to 2 mL of streptavidin-coated Sepharose beads
by agitating at room temperature for 10 minutes. Single-
stranded DNA was purified by washing the DNA with a 70%
EtOH, a denaturation solution, and a washing buffer by
using a PyroMark Q24 vacuum workstation. The single-
stranded DNA was then incubated with 0.3 mM sequencing
primer (HuN9NA-292&294-R893-seq) in 25 mL of a PyroMark
annealing buffer at 80C for 2 minutes, and then cooled to
room temperature for at least 5 minutes. Pyrosequencing
reactions were performed on the PyroMark Q24 instrument
by using the allele quantification mode of PyroMark version
2.0.6 software (Qiagen).
Results
Sensitivity and specificity of reverse transcription-
PCR in detecting NA of H7N9 virus
The NA gene of this emerging H7N9 virus is known to be
derived from the Eurasian lineage of the avian influenza
virus,8,9 and the primers for reverse transcription (RT)-PCR
were therefore designed to target to the conserved region
among the N9 subtypes of the Eurasian lineage (Fig. 1A,
Table 1). A 488-nucleotide DNA was amplified that con-
tained the 292nd codon. A serial dilution of N9 plasmid was
made to validate the RT-PCR sensitivity, in which as few as1000 copies of target DNA were detected in the agarose gel
stained by ethidium bromide (Fig. 1B). To test the speci-
ficity of our proposed RT-PCR primers, we used full-length
NA plasmids derived from each of the seasonal H1N1,
H3N2, pandemic H1N1 2009, and PR8 strain of influenza A
viruses as DNA templates for RT-PCR. All the NA plasmids
were amplified by the full length NA primers11 for complete
genome amplification, by contrast, only the N9NA plasmid
was specifically amplified by our primers without a cross-
reaction to other subtypes (Fig. 1C).Pyrosequencing for detection of the R292K
mutation
The NA mutation R292K (AGG to AAG) was found in A/
Shanghai/1/2013. In all other H7N9 strains found in
humans, however, this residue remained R (AGG). To
examine whether R or K existed in the first imported case in
Taiwan, the N9NA detection based on the RT-PCR was
performed directly on the sputum, and a specific amplified
DNA was successfully observed in the specimen as well as
the plasmid control (an NA clone derived from the H7N9
virus), but not in the reagent control (Fig. 2A). The PCR
product from the sputum was then analyzed using a pyro-
sequencing assay. Conventional Sanger sequencing was also
performed for comparison. The reverse primer (HuN9NA-
292&294-R893-seq) was used in the pyrosequencing assay.
The sequences of the pyrosequencing read out, therefore,
were reverse complements of the original sequences. As
shown in Fig. 2B, mixed nucleotides of C and T were
detected at the corresponding triplets of the residue for
292 at a ratio of 44.08% to 55.92%, in which C resulted in a
sensitive marker (CCTwas complementary/reversed to AGG
at codon 292; R292), and T resulted in a resistant marker
(CTT was complementary/reversed to AAG at codon 292;
R292K). The NA plasmid control that contained an R292K
mutation, however, showed a pure T at the corresponding
nucleotide position (Fig. 2C). This suggests that a mixed
population of different viruses was present in the sputum
specimen. The mixed nucleotide sequences were displayed
with mixed peaks by Sanger sequencing (in the right panel
of Fig. 2B), and the dominant peak (T, leading to R292K)
was automatically used in the output sequence. Similarly to
Sanger sequencing, the use of the standard nucleotide
Figure 2. Pyrosequencing for detecting R292K mutation. (A) The presence of neuraminidase (NA) in the sputum specimen
collected from the first imported Taiwanese patient was detected by reverse transcription polymerase chain reaction and analyzed
with an electrophoresis gel. (B) The polymerase chain reaction products (200 ng) amplified from the sputum and N9 plasmid were
analyzed using pyrosequencing (left subpanels) and Sanger’s sequencing method (right subpanels) by employing a reverse primer
(HuN9NA-292&294-R893-seq). The Sanger sequence readouts were in a negative sense. The positive-sensed sequence of R292
appeared as AGG and the oseltamivir-resistant marker R292 K as AAG (shown in parentheses).
468 C.-K. Mok et al.dispensation protocol for the pyrosequencing assay also
only displayed the major T nucleotide and failed to detect
the underlying mixed variants. We implemented a
customized nucleotide dispensation order (as shown in the
chromatogram in Fig. 2B) that specifically read out the 292
position signals in the N9NA pyrosequencing assay; this
yielded a successful detection of the resistant variants in
the H7N9 virus.Figure 3. The semi-nested polymerase chain reaction (PCR) impr
(A) The serially diluted cDNA from the sputum and the N9 plasmid (0
the sensitivity of the reverse transcription-PCR method. (B) After 1
the detection rate was enhanced 10-fold for the sputum and 104-fold
lowest detected samples labeled with an asterisk in panel B) by usiSemi-nested PCR improved sensitivity for the
detection of the H7N9 virus
We understand that the low sensitivity of a detection
method may yield a false-negative result. We used a semi-
nested PCR based on a nested reverse PCR primer (HuN9NA-
R919) and, after the first round of PCR, the semi-nested
PCR detected the virus cDNA in solutions that were at leastoved the sensitivity of detecting avian influenza A (H7N9) virus.
.44 pg, approximately 105 copies of DNA) were used to indicate
mL of the first PCR product was amplified in a semi-nested PCR,
for the N9 plasmid control. (C) Analyzing the PCR products (the
ng pyrosequencing showed similar results as in Fig. 2B and C.
Pyrosequencing for H7N9 oseltamivir-resistant 46910 times more diluted than the original solution. In addi-
tion, the sensitivity of the semi-nested PCR showed a 104-
fold increase in the N9 plasmid control; the plasmid is a
highly pure preparation and is more stable than the spec-
imen isolation (Fig. 3A and B). The semi-nested PCR prod-
ucts from first-round diluted samples were subsequently
analyzed using a pyrosequencing assay, and a similar ratio
of mixed nucleotides was also obtained in the specimen
shown in Fig. 2B and C.
Discussion
Oseltamivir is an effective and easy-to-use (by oral
administration) clinical drug for treating influenza. How-
ever, increasingly more reports are indicating that drug-
resistant viruses have been found in patients with or
without oseltamivir treatment. Therefore, it is critical to
detect oseltamivir-resistant markers promptly and accu-
rately to provide guidelines for clinical treatment. Many
medical virological laboratories often perform virus isola-
tion and then Sanger sequencing, which usually takes
several days. Pyrosequencing analysis reduces this process
to several hours because of its higher sensitivity for
revealing nucleotide sequence information directly from
specimens. Comparatively, several approaches have been
well-established for detecting the NA drug resistance
marker, such as the rare-variant-sensitive high-resolution
melting-curve analysis established by Chen et al,12 which
also detects with exceptional sensitivity. However, this
technique was specifically designed to detect H275Y in 2009
N1NA; its design cannot be changed arbitrarily and it is
limited to detecting only certain circulating NA subtypes.
The analysis should be specifically designed for this
emerging avian influenza A (H7N9) virus because the various
subtypes of an influenza virus can have varied NA se-
quences. Furthermore, because pyrosequencing and Sanger
sequencing are both primer-based design analysis methods,
both possess easily designed sets of primers with which to
establish the detection purpose.
We implemented a highly specific and sensitive pyrose-
quencing assay to detect the oseltamivir-resistant markers
in the sputum specimen collected from the first imported
human H7N9 case in Taiwan. We located R292K in the form
of a viral quasispecies. In this case, other NA inhibitors,
such as zanamivir and peramivir, should be considered
alternative drugs for patient treatment.
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